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Mutations of the Janus family kinase JAK3 gene
cause severe combined immunodeficiency (SCID).
JAK3 deficiency in humans is characterized by the
absence of circulating T cells and natural killer (NK)
cells with normal numbers of poorly functioning B
cells (T–B+NK–). Using SCID patient-specific induced
pluripotent stem cells (iPSCs) and a T cell in vitro dif-
ferentiation system, we demonstrate a complete
block in early T cell development of JAK3-deficient
cells. Correction of the JAK3 mutation by CRISPR/
Cas9-enhanced gene targeting restores normal
T cell development, including the production of
mature T cell populations with a broad T cell receptor
(TCR) repertoire. Whole-genome sequencing of
corrected cells demonstrates no CRISPR/Cas9 off-
target modifications. These studies describe an
approach for the study of human lymphopoiesis
and provide a foundation for gene correction therapy
in humans with immunodeficiencies.INTRODUCTION
Severe combined immunodeficiency (SCID) describes patients
with severe defects in T cells with or without accompanying
defects in B cells. Naturally occurring mutations in the JAK3
gene (autosomal recessive) and the X-linked common gamma
chain gC gene (IL-2RG) are the most common T
–B+ immunodefi-
ciencies. Gene ablation experiments in mice demonstrate that
Jak3 is critical for early T cell differentiation and Jak3 knockout
mice were found to have severely reduced numbers of mature B
cells in the bone marrow and in the periphery (Nosaka et al.,
1995; Thomis et al., 1995). The similarity of phenotypes of gc
and JAK3 SCID suggests that the primary function of JAK3 is to
transduce signals from gc-dependent cytokine receptors (IL-2R,1668 Cell Reports 12, 1668–1677, September 8, 2015 ª2015 The AuIL-4R, IL-7R, IL-9R, IL-15RA, and IL-21R) to transcription factors
(STATs) that activate downstream genes. Mice lacking Jak3 have
a profound decrease in thymus cellularity. However, the residual
thymocytes proceed to develop into mature T cells and reconsti-
tute theperipheral population. Incontrast, JAK3-deficientpatients
have few, if any, peripheral T cells (Notarangelo et al., 2001; Rus-
sell et al., 1995). Todate, little is knownabout howJAK3mutations
affect human lymphocyte progenitor development.
Allogeneic hematopoietic stem cell transplantation is currently
the only established therapy for SCID; however, delayed immune
recovery and graft-versus-host disease present significant risks
(Pai et al., 2014). Treatment by retroviral-based gene therapy has
been successfully demonstrated for X-linked SCID (Hacein-Bey-
Abina et al., 2014) and ADA-SCID (Ferrua et al., 2010). However,
severe adverse effects of insertional mutagenesis have been
observed with retroviral gene therapy (Hacein-Bey-Abina et al.,
2003, 2008). Self-inactivating lentiviral vectors have been used
effectively in recent clinical trials, but long-term follow-up is
needed to thoroughly address safety concerns (Aiuti et al.,
2009; Biffi et al., 2013; Sauer et al., 2014). An alternative thera-
peutic strategy is one in which patient-specific induced plurip-
otent stem cells (iPSCs) are derived, and disease-causing
mutations are corrected by gene targeting (Takahashi et al.,
2007; Takahashi and Yamanaka, 2006; Yu et al., 2007). These
corrected iPSCs could then be differentiated into hematopoietic
progenitors for transplantation into patients to treat the disease
(Hanna et al., 2007). The recent development of CRISPR/Cas9-
enhanced gene targeting dramatically advances the practicality
of this strategy (Cong et al., 2013; Mali et al., 2013).
IPSC technology combined with in vitro differentiation sys-
tems also provides a powerful platform to recapitulate in vivo
development. We and other groups have shown that OP9
stromal cells transduced with Notch ligand Delta-like-1 or
Delta-like-4 (OP9-DL1/4) can contribute to a T cell inductive
environment (Chang et al., 2014; Schmitt et al., 2004; Schmitt
and Zu´n˜iga-Pflucker, 2002). OP9-DL1/4 cells efficiently induce
T lymphopoiesis from iPSC-derived CD34+ hematopoietic pro-
genitor cells (HPCs), and these HPCs can be differentiated intothors
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Figure 1. In Vitro Differentiation of JAK3
C1837T Patient iPSCs Recapitulates SCID
Phenotypes
(A) Flow cytometry of iPSC-derived T cells. JAK3
WT iPSCs (Control) and JAK3-deficient iPSCs
(JAK3 C1837T) were differentiated into CD34+ cells
on OP9 stromal cells and, subsequently, into NK
and T cells on OP9-DL4 monolayers. T and NK cell
differentiation from JAK3-deficient iPSCs was
dramatically decreased compared to controls; only
a small population of CD7+CD16–CD56– T cells or
CD7+CD16+CD56+ NK cells was observed at T cell
induction day 14.
(B) Diagram of early T cell development. In the
thymus, early T cell progenitors (ETP) differen-
tiate from CD4–CD8– double-negative (DN) to
CD4+CD8+ double-positive (DP) and, subse-
quently, to CD4+ or CD8+ single-positive stages. In
an alternative pathway, early T cell progenitors
differentiate into NK cells; the dotted line in-
dicates multiple steps in the pathway to mature
CD7+CD16+CD56+ NK cells.
(C) RT-qPCR assays for transcripts of key genes
that regulate early events during specification of
the T cell lineage. RNA levels are shown relative
to GAPDH expression. Data are shown as the
mean ± SD. *p < 0.05 (t test).
(D) Flow cytometry of iPSC-derived T cells. JAK3
WT iPSCs (Control) and JAK3-deficient iPSCs
(JAK3 C1837T) were differentiated into CD34+ cells
onOP9 stromal cells and, subsequently, into T cells
onOP9-DL4monolayers. At T cell induction day 28,
no CD4+CD8+ DP, CD4+ SP, or CD8+ SP T cells
were detected (top), and neither CD3 or TCRab
were expressed in JAK3-deficient iPSC-derived
T cells (JAK3 C1837T) (lower).functional CD8 T cells (Dervovic et al., 2012). Despite the lack of
proper major histocompatibility complex (MHC) expression on
OP9 cells, the OP9-DL1/4 system has provided a valuable
method to study early T cell commitment and thymocyte matu-
ration in vitro (de Pooter and Zu´n˜iga-Pflucker, 2007).
In this paper, we demonstrate that differentiation of JAK3-defi-
cient human T cells is blocked at an early developmental stage.
Similar to previous studies in mouse models, JAK3-deficient
early human T cell progenitors undergo apoptosis at a high rate
due to lowexpression ofBCL2.Wealso demonstrate that correc-
tion of the human JAK3 mutation by CRISPR/Cas9-enhanced
gene targeting restores the differentiation potential of early
T cell progenitors. These corrected progenitors are capable of
producing NK cells and mature T cell populations expressing a
broad repertoire of T cell antigen receptors (TCRs). These studies
establish a powerful system for determining the mechanism of
immunodeficiency in human SCID patients and for testing phar-
macological and genetic therapies for the disorder.
RESULTS
JAK3-Deficient Human T Cells Express Low Levels of
BCL2 and Die at an Early Developmental Stage
IPSCs were generated from skin keratinocytes (Chang et al.,
2009) of a SCIDpatient homozygous for aC>T nucleotide substi-Cell Retution in exon 14 of the JAK3 gene. This mutation replaces a CGA
codon (arginine at 613) with a TGA stop codon (p.R613X). The
4-month-old patient presentedwith a T–B+NK– clinical phenotype
(see Experimental Procedures). To determine whether this SCID
phenotype canbe recapitulated in vitro,we attempted to differen-
tiate patient-specific iPSCs to T lymphocytes using our previously
published two-step OP9 and OP9-DL4 system (Chang et al.,
2014). JAK3-deficient iPSCs grew at a rate comparable to control
iPSCs derived from healthy donors, and these iPSCs efficiently
differentiated into CD34+ hematopoietic progenitors (HPs) on
OP9 stromal cellmonolayers. However, when the JAK3-deficient,
iPSC-derived CD34+ HPs were plated onto OP9-DL4 stromal
monolayers, NK and T cell differentiation was dramatically
decreased compared to controls (Figure 1A). Only a small popu-
lation of CD7+CD16–CD56– T cells or CD7+CD16+CD56+ NK cells
was observed at T cell induction day 14 (Figure 1A).
The transitions of early T cell progenitors (ETPs) from
CD4–CD8– double-negative (DN)/ CD4+CD8+ double-positive
(DP) / CD4+ single-positive (SP) or CD8+ single-positive (SP)
T cells are directed by precise activation and repression of spe-
cific transcription factors (Rothenberg et al., 2008) (Figure 1B). In
control cells (Figure 1C), silencing of PU.1 gene expression and
induction of GATA3 and BCL11B gene expression direct early
hematopoietic progenitors to proceed to the onset of T lineage
commitment. In JAK3-deficient cells, expression of the PU.1ports 12, 1668–1677, September 8, 2015 ª2015 The Authors 1669
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Figure 2. BCL2 Partially Rescues T Cell
Developmental Defects in JAK3-Deficient,
In-Vitro-Derived Cells
(A) Apoptosis of JAK3-deficient, iPSC-derived
T cells compared to JAK3 WT controls. Annexin
V-positive cells were analyzed at T cell induction
day 10 (TD10) and 17 (TD17). Four independent
experiments were performed with control JAK3WT
cells (Control, light blue), and five independent
experiments were performed with JAK3-deficient
cells (JAK3 C1837T, dark blue). Data are shown as
the mean ± SD. *p < 0.005 (t test).
(B) RT-qPCR assays for anti-apoptotic BCL2 and
pro-apoptotic BAX expression in two lines (1 and 2)
from JAK3 WT (Control) and JAK3-deficient cells
(JAK3 C1837T). ND, not detected. RNA levels are
shown relative to GAPDH expression.
(C) Flow cytometry of JAK3-deficient iPSC-derived
T cells transduced with BCL2-2A-GFP lentivirus to
assess effects on NK (CD16+56+) and T cell (CD3+)
development and on CD4+CD8+ DP to CD4+ SP or
CD8+ SP T cell maturation. (top right of C) Western
blot of BCL2 protein in GFP– and GFP+ sorted
populations.gene was not completely silenced, induction of the GATA3 and
BCL11B genes was significantly lower than controls, and T cell
specification was severely limited. However, low-level expres-
sion of the T cell-specific genes RAG1, RAG2, and PTCRA sug-
gests that JAK3-deficient cells can progress at low efficiency to
an early T cell progenitor stage. Jak3 knockout (KO) mice have a
small thymus due to a block in thymocyte differentiation at the
CD4–CD8– double-negative 2 (DN2) stage prior to productive
TCR rearrangement. Interestingly, some residual thymocytes in
Jak3 knockout (KO) mice develop into mature T cells and recon-
stitute the peripheral population (Eynon et al., 1999); this does
not occur in human JAK3-deficient patients. To further under-
stand the developmental defects resulting from JAK3 deficiency
in humans, we assayed T cell lineage commitment and matura-
tion in JAK3-deficient cells compared to normal JAK3 WT
controls. IPSC-derived CD34+ cells were plated onto OP9-DL4
monolayers, and cells were harvested and analyzed for lympho-1670 Cell Reports 12, 1668–1677, September 8, 2015 ª2015 The Authorscyte markers at T cell induction day 28.
No CD4+CD8+ DP, CD4+ SP, or CD8+ SP
T cells were detected in JAK3-deficient
cells. Moreover, CD3 and TCR ab were
not significantly detected in JAK3-defi-
cient cells (Figure 1D). The complete
absence of CD4+CD8+ cells indicates
that human JAK3-deficient cells arrest at
the CD4–CD8– DN stage. Low expression
of the DN3-associated genes PTCRA,
RAG1, and RAG2 suggests that human
JAK3-deficient cells arrest at or before
the DN2 stage. Unlike the results in Jak3
KO mice in which residual thymocytes
develop past the CD4–CD8– DN stage
into mature T cells that partially reconsti-
tute the peripheral blood system, ourdata demonstrate a complete block of T cell development in hu-
man JAK3-deficient cells. This block is consistent with the
absence of mature T cells in peripheral blood of JAK3-deficient
human SCID patients.
The profound defects in lymphocyte development of JAK3-
deficient cells can be explained by the absence of IL-7 signaling,
which plays an important role in lymphoid progenitor survival (Li
et al., 2004; von Freeden-Jeffry et al., 1997) and differentiation
(Kang et al., 1999). IL-7/JAK3 signaling maintains thymocyte ho-
meostasis by regulating the BCL2 family of apoptotic regulators.
Thymocytes and peripheral T cells from Jak3 KO mice have a
high apoptotic index in part through selectively elevating Bax,
a pro-apoptotic factor, and by reducing expression of Bcl2, an
anti-apoptotic factor (Wen et al., 2001). Similarly, we observed
an increase in apoptosis of in-vitro-derived human JAK3-defi-
cient cells compared to controls at T cell induction day 10
(9%–2.2%) and T cell induction day 17 (7%–1.9%) (Figure 2A).
Consistent with this phenotype, BAX levels were increased and
BCL2 levels were reduced in JAK3-deficient cells compared to
controls (Figure 2B).
Forced expression of Bcl2 rescues T but not B or NK cell
development in gc-deficient mice (Kondo et al., 1997). Trans-
plantation of Jak3 KO mice with Bcl2-expressing Jak3 KO
bone marrow cells also improves peripheral T cell numbers
(Wen et al., 2001). To determine whether overexpression of
BCL2 rescues the T cell developmental defects of human
JAK3-deficient cells, we transduced in-vitro-derived, JAK3-defi-
cient CD34+ cells with a lentivirus containing a BCL2-2A-GFP
polycistron driven by the EF1a promoter. After transduction,
CD34+ cells were plated ontoOP9-DL4monolayers and assayed
for NK and T cell markers at T cell induction day 28. No
CD3–CD16+CD56+ NK cells were found in GFP– (JAK3–; BCL2
low) or GFP+ cells (JAK3–; BCL2+) (Figure 2C). These findings
are consistent with reports demonstrating that the absence of
NK cells in gc-deficient and Jak3-deficient mice is due to the
lack of functional IL-15 signaling (Giri et al., 1994) and is indepen-
dent of Bcl2-mediated anti-apoptosis. CD3+ cells were only
detected in GFP+ (JAK3–; BCL2+) cells suggesting that BCL2
released the developmental block at the DN stage in JAK3-defi-
cient cells. Interestingly, a second developmental arrest was
evident at the DP stage; no further differentiation of CD8+CD4+
DP cells was observed in GFP+ cells (Figure 2C). These data
are consistent with recent demonstrations that signaling by intra-
thymic IL-7 is necessary for CD8 lineage specification of DP thy-
mocytes (Hare et al., 2000; Park et al., 2010).
In summary, the studies described above demonstrate that
human SCID phenotypes can be recapitulated in vitro with
patient-derived iPSCs. JAK3 deficiency results in proliferative
defects in DN thymocytes. Forced expression of BCL2
enhances survival of DN cells, which further differentiate into
DP thymocytes. Nevertheless, DP thymocytes fail to mature to
SP T cells, and this defect may result from the absence of IL-7/
JAK3 signaling.
Correction of the JAK3 Deficiency in SCID Human
Induced Pluripotent Stem Cells by CRISPR/
Cas9-Enhanced Gene Targeting
To determine whether normal T cell development can be
restored in JAK3-deficient SCID patient cells, we corrected the
JAK3 mutation in iPSCs by CRISPR/Cas9-enhanced gene tar-
geting. Six guide RNAs within introns upstream and downstream
of exon 14 were designed to target wild-type Cas9 or the D10A
Cas9 nickase near the C1837T mutation, and a correction tem-
plate was used for homology-directed repair (HDR) (Figure 3A).
IPSCs were nucleofected with two plasmids expressing the
D10A Cas9 nickase and paired guide RNAs or a single plasmid
expressing wild-type Cas9 and a single guide RNA. Cells were
grown in medium containing G418 for 2 weeks post nucleofec-
tion. Individual colonies were picked, expanded, and genotyped
by PCR (Figure 3B, top). The efficiency of CRISPR/Cas9-medi-
ated JAK3 gene correction is shown in Figure 3C. Three clones
from wild-type Cas9 + gRNA #1, three clones from wild-type
Cas9 + gRNA #2, and six clones from D10A Cas9 nickase +
paired gRNAs #1 and #2 were further verified by Sanger
sequencing. In 12 sequenced clones, two homozygous cor-Cell Rerected clones (one clone from D10A Cas9 nickase + paired
gRNA #1 and #2 and one clone from wild-type Cas9 + gRNA
#1) and ten heterozygous corrected clones were identified (Fig-
ure 3D). Restoration of JAK3 gene expression was demonstrated
by RT-PCR (JAK3 mRNA) (Figure 3B, lower-left panel) and west-
ern blot (JAK3 protein) (Figure 3B, lower right).
Specificity of CRISPR/Cas9-Directed JAK3 Correction
The potential for off-target, CRISPR/Cas9-directed genome
modifications raises some concerns about the use of this
approach for therapy in humans. In cancer cell lines, relatively
high levels of off-target mutagenesis by Cas9-gRNAs have
been described (Fu et al., 2013). However, several groups have
recently demonstrated by whole-genome sequencing (WGS)
that off-target modifications are rare in human iPSCs and human
embryonic stem cells (Smith et al., 2014; Veres et al., 2014). To
determine the specificity of CRISPR/Cas9-directed JAK3
correction in human SCID iPSCs, we performed WGS before
and after gene correction. The genomes of two heterozygous
and one homozygous corrected clones were sequenced. The
two heterozygous clones were corrected with gRNA #2 + wild-
type Cas9, and the homozygous clone was corrected with
gRNA #1 + gRNA #2 + D10A nickase Cas9.
The 20-base CRISPR guide sequences were mapped to the
human reference genome, allowing up to three mismatches in
order to identify potential off-target sites (Table 1; Figure S1).
These sites were then analyzed for variations in the iPSC
samples following CRISPR/Cas9-directed gene correction.
Whole-genome sequencing of the one homozygous and two
heterozygous corrected iPSC lines demonstrated that no muta-
tions (SNVs nor indels) were introduced into the 1,450 potential
off-target sites (Table 2). These results demonstrate the speci-
ficity of CRISPR/Cas9-directed gene correction.
Restoration of T Cell Development after CRISPR/
Cas9-Directed JAK3 Correction
To determine whether T cell development is restored after
JAK3 gene correction, NK and T cell generation were verified,
and T cell lineage commitment and maturation were analyzed.
We and other groups have previously demonstrated in the
OP9-DL4 in vitro system that T cell differentiation sequentially
passes through intermediates observed in vivo: CD34+CD7+
T/NK committed stage; CD7+CD4+CD8 immature, SP stage;
CD4+CD8+ DP stage; and finally, CD3+CD8+ TCRab mature
stage. Mature T cells are polyclonal, proliferate, and secrete cy-
tokines in response to mitogens (Chang et al., 2014; Timmer-
mans et al., 2009). Therefore, control, JAK3-deficient, and
JAK3-corrected human iPSCs were differentiated into hemato-
poietic progenitors on OP9 monolayers, and CD34+ cells were
positively selected with anti-CD34 magnetic beads. These cells
were plated onto OP9-DL4 monolayers, and non-adherent cells
were analyzed for lymphocyte markers at T cell induction day
(TD) 14, 21, 28, and 35 (Figure 4). In normal controls (green
line), 1.23 107 CD7+ cells (84% of cells counted in the lymphoid
gate) were generated at T cell induction day 14 from 1–2 3 106
CD34+ cells. At this stage, about 20% of CD7+ cells were
CD7+CD16+CD56+ NK cells (2.4 3 106). T cell markers CD4,
CD8, CD3, and TCR ab were sequentially detected upon T cellports 12, 1668–1677, September 8, 2015 ª2015 The Authors 1671
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Figure 3. CRISPR/Cas9-Enhanced Correc-
tion of the JAK3 C1837T Mutation in Pa-
tient-Specific iPSCs
(A) Strategy for genome modification using
CRISPR/Cas9 to induce double-strand breaks in
the JAK3 locus and a correction template for
homology-directed repair. Top line, structure of the
JAK3 gene. Open boxes, exons. Red asterisk,
C1837T mutation. Blue arrows, guide RNAs.
(B) (top) PCR analysis demonstrating homologous
recombination; primers for 50 and 30 analysis are
indicated by green arrows. (lower left) RT-PCR
analysis demonstrating JAK3 mRNA expression in
JAK3WT (Control), JAK3-deficient (JAK3 C1837T),
and corrected (JAK3 Corrected) T cells. (lower
right) Western blot analysis demonstrating JAK3
protein expression in JAK3 WT (Control), JAK3-
deficient (JAK3 C1837T), and corrected (JAK3
Corrected) T cells. JAK3/GAPDH ratios were
quantified with ImageLab software (Bio-Rad).
(C) Summary of targeting efficiencies of guide
RNAs.
(D) Sanger sequencing of the PCR amplicons from
parental JAK3 iPSCs (left), heterozygous corrected
(middle), and homozygous corrected iPSCs (right).
The heterozygous clone was corrected with wild-
type Cas9 + gRNA#2, and the homozygous clone
was corrected with D10A Cas9 nickase + gRNA#1
and #2.maturation. As we reported previously, at T cell induction day 35
the NK population decreased (6.93 104), and more than 50% of
residual cells were CD8 SP cells (1.2 3 106). In JAK3-deficient
cells (blue line), only 4.53 104 CD7+ cells (38.9%of cells counted
in lymphoid gate) were generated at T cell induction day 14
from 1–2 3 106 CD34+ cells. The number of total CD7+ cells
decreased during extended culture and T cell markers CD3,
CD4, CD8, and TCR ab were not significantly expressed.
Similar to control cells, 1–23 106 CD34+ JAK3-corrected cells
differentiated into 4.7 3 106 CD7+ cells (91% of cells counted in
lymphoid gate) at T cell induction day 14 including 4.3 3 105
CD7+CD16+CD56+ NK cells. After further differentiation to
TD21, TD28, and TD35, T cell maturation markers CD3, CD4,
CD8, and TCR ab were abundantly observed (Figure 4). Our
data indicate that JAK3-corrected iPSCs generate NK and
T cells with similar efficiency.
To determine whether TCR rearrangement is reestablished in
JAK3-corrected T cells, TCR Vb typing was performed by flow1672 Cell Reports 12, 1668–1677, September 8, 2015 ª2015 The Authorscytometry and summarized in Figure 5A.
JAK3-corrected T cells expressed all 21
of the Vb segments that we tested there-
fore, a broad TCR repertoire was restored.
Finally, we examined the integrity of the
TCR signaling pathway, a surrogate of
T cell function, in JAK3-corrected T cells
by measuring cell surface activation
markers following anti-CD3/CD28 stimu-
lation. On day 3 post-stimulation, the
percentage of CD3+CD25+CD69+ T cells
increased from 0.68% to 59.7% in JAK3-corrected T cells, similar to the increase observed in control cells
(0.01%–37.6%) (Figure 5B). These data and results described
above demonstrate that correction of the JAK3 C1837T
(p.R613X) mutation by CRISPR/Cas9-enhanced gene targeting
in an in vitro iPSC model system restores normal T cell develop-
ment with the capacity to produce functional, mature T cell pop-
ulations with a broad TCR repertoire.
DISCUSSION
Muchhasbeen learnedabout lymphopoiesis in thepast2decades
fromnaturally occurring immunodeficientmice and fromknockout
and knockin mouse models. These data have provided funda-
mental knowledge about the mechanisms involved in lymphocyte
development and activity. In humans, the phenotype of lympho-
cytes in the peripheral blood of SCID patients has been well
described, but studies on critical steps of lymphoid commitment
and thymocyte development have been difficult to perform.
Table 1. Identification of Potential Off-Target Sites
gRNA#l gRNA#2
Sequence GTGAGATACAGATACAGACA AATGATTTGCCTGGAATGCC
Target sites (0 mismatch) 1 1
1 base mismatch, potential off-target sites 3 0
2 base mismatch, potential off-target sites 80 13
3 base mismatch, potential off-target sites 1,109 243
Total 1,193 257
Potential off-target sites were identified by aligning the CRISPR/Cas9 guide sequences to the hg19 reference genome using EMBOSS fuzznuc
software (v.6.6.0.0) (Rice et al., 2000) and allowing for a maximum of three mismatches.Access to bone marrow and thymocyte samples from untreated
patients with SCID is challenging since these conditions are
rare and infants typically present with life-threatening infections
requiring urgent HSC transplantation to survive. The strategy that
wedescribe for studyinghumanSCIDbypasses these restrictions;
large numbers of hematopoietic progenitors can be produced
from patient-specific iPSCs in vitro, and the mechanisms respon-
sible for immunodeficiency can be precisely determined. In this
study, we demonstrate that T cell development in human JAK3-
deficient SCID is completely blocked before or at the CD4–CD8–
(DN2) stage. Interestingly, forced expression of BCL2 enhances
survival ofDNcells,which further differentiate intoDP thymocytes.
However, DP thymocytes fail to mature to SP T cells, and this
defect may result from the absence of IL-7/JAK3 signaling.
We also demonstrate that correction of the human JAK3
mutation by CRISPR/Cas9-enhanced gene targeting restores
the differentiation potential of early T cell progenitors. Corrected
progenitors are capable of producing NK cells and mature T cell
populations expressing a broad TCR repertoire. Whole-genome
sequencing of one homozygous and two heterozygous cor-
rected iPSC lines demonstrates that no mutations (SNVs nor
indels) are introduced into 1,450 potential off-target sites, sug-
gesting a strong specificity for CRISPR/Cas9-directed gene
correction. In summary, these studies describe an approach
for the study of human lymphopoiesis and provide a foundation
for gene correction therapy in humans with immunodeficienciesTable 2. Variant Analysis of Potential Off-Target Sites
Clone 1 Clone 2 Clone 3
Cas9 wild-type wild-type D10A nickase
gRNA gRNA#2 gRNA#2 gRNA#l+gRNA#2
JAK3 C1837T genotype C/T C/T C/C
Discordant variants in
off-targets and flanking
100 bases
0 0 0
Whole-genome sequencing (WGS) was performed on three corrected
iPSC clones and the uncorrected control (see Whole-Genome
Sequencing and Analysis in Experimental Procedures). Variants (from
the reference genome) that were common to all four iPSC samples
were excluded from further analysis. The remainder were screened to
determine whether these variants were located in potential off-target
sites. No variants were observed in potential off-target sites. BEDTools
(v.2.17.0) (Quinlan and Hall, 2010) was used to search for non-excluded
variants in potential off-target sites.
Cell Reand other monogenic disorders. For gene therapy, we envision
transplantation of the CD34+ cells that are generated in the first
phase of in vitro culture. These cells include early multipotent he-
matopoietic progenitors that generate all myeloid and erythroid
cells in colony forming assays in addition to the lymphoid cells
that we describe here. Our results suggest that there are no
intrinsic defects in lineage specification of early hematopoietic
progenitors produced in vitro. However, we have not been able
to generate all of these lineages after transplantation into immu-
nodeficient (NSG) mice. These results suggest that human he-
matopoietic progenitors produced in vitro do not home tomouse
bone marrow niches that support self-renewal. However, these
early progenitors may be incorporated into human bone marrow
niches to which endogenous progenitors naturally home. After
safety studies are completed in NSG mice, phase 1 clinical trials
will be required to determine whether these early progenitors are
capable of engraftment and sustained reconstitution of multiline-
age hematopoiesis in human patients.
EXPERIMENTAL PROCEDURES
Patient Information
The patient was enrolled in an institutional review board-approved study, and
parents signed consents, in accordance with the Declaration of Helsinki. The
family history was negative for immune deficiencies. For the first 8 months of
age, he had poor weight gain, diarrhea, and recurrent bronchiolitis requiring
frequent hospitalization. He was admitted to the hospital at 8 months of age
with severe respiratory distress and oral thrush. Bronchoscopy with bronchial
alveolar lavage demonstrated bacterial (pseudomonas, H flu, S. pneumonia)
and viral organisms (respiratory syncytial virus). Immunologic evaluations
demonstrated severe hypogammaglobulinemia, with an immunoglobulin E
(IgE) <3 ml/ml, IgA <4 mg/dl, IgG = 29 mg/dl, IgM = 26 mg/dl. Immune pheno-
typing of peripheral blood demonstrated complete absence of CD3+ T cells
and NK cells, though B cells were present (absolute B cell count = 875 ml).
Mitogen studies demonstrated a complete lack of response to concanavalin
A, pokeweed mitogen and phytohemagglutinin A. The diagnosis of SCID
was confirmed by genetic testing, which indicated a homozygous C > T nucle-
otide substitution in exon 14 of the JAK3 gene, resulting in the replacement of
an arginine codon (CGA) with a stop codon (TGA) at amino acid position 613.
This is the first report linking this JAK3 variant (rs149316157) to a clinical case
of SCID. The patient underwent a reduced intensity conditioning matched un-
related bone marrow transplant and is doing well now two years off therapy
with complete immune reconstitution.
Human iPSC Reprogramming and Characterization
For iPSC induction, 53 104 primary keratinocytes were seeded into onewell of
a 6-well plate. On the following day, keratinocytes were transducedwith 1ml of
virus supernatant and 1 ml of human keratinocyte medium containing poly-
brene at a final concentration of 4 mg/ml. The keratinocytes were spinfectedports 12, 1668–1677, September 8, 2015 ª2015 The Authors 1673
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Figure 4. In Vitro Differentiation of JAK3-
Corrected Patient iPSCs Produces NK Cell
and T Cells with Phenotypic and Functional
Characteristics of Mature T Cells
Expression of NK cell and T cell developmental
markers in JAK3 WT (Control, green, n = 3), JAK3-
deficient (JAK3 C1837T, blue, n = 5), and JAK3-
corrected (JAK3 Corrected, orange, n = 6) T cells.
Cells were stained with the indicated antibodies
and analyzed by flow cytometry at T cell induction
days 14, 21, 28, and 35 (TD 14, 21, 28 and 35). Data
are shown as the mean ± SD.at 8003 g for 45 min (day 1). The transduction procedure was repeated again
the next day. On day 3, cells were changed to fresh human keratinocyte me-
diumandcultured for 2moredays.Onday 5, the keratinocyteswere trypsinized
and transferred to a 10-cm dish pre-seeded with mitomycin C-treated murine
embryonic fibroblasts (MEFs) and cultured in human keratinocyte medium.
On day 7, cells were changed to human embryonic stem (ES) medium and
continuously cultured on the same dish for 3–4 weeks. ES medium was
changed daily. Potential iPSC colonieswere visible after 2–3weeks. These col-
onies were individually picked and expanded on MEFs for analysis. To remove
the integrated lentiviral and polycistronic sequences, iPSCs were infected with
a Cre-expressing adenovirus (rAd-Cre-IE). Individual colonies were picked and
Cre-mediated removal of floxed sequences was verified by PCR using the
primers gctaattcactcccaaagaagacaag and cttcagcaagccgagtcctg (Figure S2).
Generation of CD34+ Cells and T Cells with OP9 Co-culture
The procedure was described previously (Chang et al., 2014) with the following
modifications. Cultures of human inducedpluripotent stemcells (hiPSCs) in one
well of 6-well plate were treated as described by Ohnuki and Yamanaka (2009)
with collagenase-trypsin-knockout serum replacement (CTK-KSR) solution to
make small cell clumps. Cell clumps were then transferred to a 10-cm plate
that was pre-seeded with 2-day old OP9 cells in a-MEM-based medium con-
taining 10% FBS, 1 3 penicillin/streptomycin and 100 mM mono-thioglycerol.1674 Cell Reports 12, 1668–1677, September 8, 2015 ª2015 The AuthorsThemediumwaschangedeveryotherday,andcells
were cultured for 18 dayswithout any splitting. After
18 days of co-culture, cells were harvested by treat-
ingwith dissociation solution (0.15%collagenase IV
and 0.015% hyaluronidase in a-MEM medium) for
about 30 min and followed by 0.25% trypsin for
another 30 min. CD34+ cells were then purified on
anti-CD34+ magnetic beads (MicroBead Kit; Milte-
nyi Biotec). For T cell differentiation, these CD34+
cells were plated onto OP9-DL4 cells and cultured
with a-MEM medium containing 20% FBS,
5 ng/ml hFlt3-L, 5 ng/ml hIL-7, and 10 ng/ml hSCF.
The medium was changed every other day, and
cells were transferred to newOP9-DL4 plates every
4 days. After completion of our studies,Menon et al.
(2015) described the correction of SCID-X1 patient-
derived iPSCs by TALENs and the generation of
mature NK cells and T cell precursors.
T Cell Stimulation
In vitro derived T cells from hiPSCs were stimulated
by incubation with CD3/28 beads (Invitrogen) ac-
cording to the manufacturer’s protocol for 3 days
prior to analysis by flow cytometry, as previously
described (Chang et al., 2014).
Flow Cytometry
Cells were harvested and washed before analysis
with an LSRFortessa cell analyzer (BD Bioscience).For cell surface staining, propidium iodide (PI, Sigma-Aldrich) was used to
exclude dead cells. For the apoptosis assay, harvested cells were first stained
with cell surface antibodies for 30 min. After washing once with 1 3 PBS, the
cells were resuspended in 100 ml of Annexin Binding Buffer (Invitrogen) con-
taining Annexin V-647 (Invitrogen) and PI and incubated for 15min before add-
ing 400 ml of Annexin Binding Buffer with PI. Antibodies were obtained fromBD
Biosciences unless otherwise indicated: CD3 (Percp-Cy5-5, clone UCHT1),
CD4 (PE-Cy7, clone SK3), CD7 (APC, BV510, clone M-T701), CD8 (APC-
Cy7, clone SK1), CD16 (PE, clone B73.1), CD25 (FITC, clone 2A3), CD34
(PE-Cy7, clone WM59), CD43 (PE, clone 1G10), CD56-PE (clone MY31),
CD69 (FITC, clone L78), TCR-ab (FITC, PE, clone T10B9.1A-31), Beta Mark
TCR Repertoire Kit (Beckman Coulter).
Vector Construction
The polycistronic OSKM vector was previously described (Chang et al., 2009).
The Lenti-hDL4-mCherry plasmid was constructed by cloning a PCR-ampli-
fied human DL4 cDNA (Open Biosystems), an IRES fragment (Open Bio-
systems) and mCherry cDNA into a lentiviral vector (pDL171) which contains
the EF1a promoter. PCRs were performed using PrimeStar polymerase
(Takara). To construct CRISPR plasmids, we cloned designed gRNA oligos
into pX330 and pX335 plasmids following the Zhang lab protocol (Addgene).
The list of primers for construction of gRNA sequences is as follows: (1)
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Figure 5. In Vitro Differentiation of JAK3-Corrected Patient iPSCs
Produces T Cells with Phenotypic and Functional Characteristics of
Mature T Cells
(A) T cell receptor (TCR) Vb analysis of JAK3-corrected T cells. A highly diverse
repertoire of TCR Vb is represented in T cells derived from corrected SCID
patient iPSCs.
(B) Flow cytometry demonstrating T cell activation in JAK3-corrected
T cells. T cells derived from JAK3 WT (Control) and JAK3-corrected
iPSCs were stimulated with anti-CD3/28 beads for 3 days before analysis
of activation markers CD25 and CD69. Matched isotype antibodies were
used as negative controls (isotype). These data were gated on CD3+
populations.gRNA-F1: caccGTG AGA TACAGA TACAGACA, (2) gRNA-R1: aaacTGTCTG
TAT CTG TAT CTC AC, (3) gRNA-F2: caccgAAT GAT TTG CCT GGA ATG CC,
(4) gRNA-R2: aaacGGC ATT CCA GGC AAA TCA TTc, (5) gRNA-F3: caccg
CAG CCT AGG CAA AGG CCT GC, (6) gRNA-R3: aaacGCA GGC CTT TGC
CTA GGC TGc, (7) gRNA-F4: caccgTGC CAA CAG AAC TGC CTG AT, (8)
gRNA-R4: aaacATC AGG CAG TTC TGT TGG Cac, (9) gRNA-F5: caccGAC
CAG GGT GCA AGT GTG GA, (10) gRNA-R5: aaacTCC ACA CTT GCA CCC
TGG TC, (11) gRNA-F6: caccGCT CCT CAG CCT GGC ATT CA, and (12)
gRNA-R6: aaacTGA ATG CCA GGC TGA GGA GC. To construct the JAK3
repair plasmid, wild-type human genomic DNA was PCR amplified using
JAK3 primer sets (50 arm, forward: gtcgacgtcgacgctcagtgaagctgaagtattcctt
ctgcttcacagggcgaccactac and 50 arm, reverse: atttaaatcctcccctcgaacccttac
caaactcctatgcatactacag; 30 arm, forward: ttaattaattaattagcattttaggttcaggttgt
gagaacactagaagagaacaagtca and 30 arm, reverse: gtatacgtatacgcatacctg
gagaggggacaaggtcttgagatgcgagggt).
After digesting with enzymes (50 arm, SalI and SwaI; 30 arm, PacI and
BstZ17I), the PCR products were cloned into a plasmid containing a LoxP-
PGK-Neo-LoxP fragment. All of the oligos used in this study were synthesized
by Integrated DNA Technologies (IDT). To construct the BCL2 lentiviral
plasmid, a primer set (forward: agccaccttaattaagccaccatggcgcacgctggga
gaacggggtacgata and reverse: taacagagagaagttcgtggctccggatcccttgtggcc
cagataggcacccagggtgat) was used to amplify the human BCL2 cDNA (Open
Biosystems) fragment. The amplified product was linked to GFP through a
2A sequence by PCR and cloned into the pDL171 vector.Cell ReCell Culture
IPSCs were cultured on mitomycin-C-treated MEFs derived from E14.5 CF-1
embryos in ES cell medium consisting of DMEM F-12 supplemented with 1 3
non-essential amino acids, 1 3 penicillin-streptomycin, 1 3 L-glutamine (all
from Mediatech), 20% Knockout Serum Replacement (Invitrogen), 2-ME
(Sigma), and 5–10 ng/ml bFGF (Invitrogen). Human primary keratinocytes
were cultured in DermaLife KMedium Complete Kit (LifeLine Cell Technology).
OP9 cells were purchased from ATCC and grown in a-MEMmedium with 20%
FBS and penicillin-streptomycin. OP9-DL4 cells were established by trans-
ducing OP9 cells with a lentivirus containing hDL4 and mCherry.
Virus Production
For preparation of lentivirus, 10 mg of the lentiviral vector, 2.5 mg of the enve-
lope plasmid (pMDG), and 7.5 mg of the packaging plasmid (pCMBVdR8.9.1)
were co-transfected into 53 106 293T cells by Fugene 6 (Roche or Promega).
Virus-containing supernatant was collected 2 days after transfection and
passed through a 0.45-mm filter.
Gene Targeting
IPSCs were treated with 0.25% trypsin for 5 min to generate single-cell sus-
pensions. After washing twice with 1 3 PBS, 1–2 million cells were mixed
with 5 mg of JAK3 repair plasmid and 5 mg of either pX330-JAK3 or pX335-
JAK3 plasmid for Nucleofection (Human Stem Cell Nucleofector Kit, program
A-023, Lonza) and subsequent plating onto MEFs. Two to 4 days later, hES
medium containing 30 mg/ml of G418 was added to the plates to select for
drug-resistant colonies. The colonies were picked 3–4 weeks post selection
and expanded for genomic DNA extraction. For genotyping, a 50 primer set
(tgctaaagcgcatgctccagact and gtcttcatctcagggtcggct) and a 30 primer set
(cctctctgtgcattatggcag and gccttctatcgccttcttg) were used. To remove
the Neo selection marker, iPSCs were infected with a Cre-expressing adeno-
virus (rAd-Cre-IE) and later analyzed by PCR for marker loss using the
following primers: Jak3-Creout-F ttgggagtgggctctgtagtatgc and Jak3-Cre-
out-R ttcttcctgcccagcctcgtcatt (Figure S2).
RT-PCR
Total RNA was isolated from in-vitro-derived cells with Trizol reagent (Invitro-
gen). cDNA was synthesized from 0.5–2 mg of total RNA using the Superscript
First-strand Synthesis System (Invitrogen) according to the manufacturer’s
instructions. SYBR Green PCR Master Mix (Life Technologies) was used for
qPCR according to themanufacturer’s instructions. All valueswere normalized
relative to GAPDH expression. Primer sets used for qPCR are GAPDH (F:
actcctccacctttgacgct, R: tcccctcttcaagggtctacatg); PU.1 (F: gtgcaaaatggaag
ggtttc, R: ggagctccgtgaagttgttc); GATA3 (F: tgtttcctttcactggccaca, R: aacggc
aactggtgaacggta); BCL11B (F: ggcgatgccagaatagatgccg, R: ccaggccacttggc
tcctctatctccaga); RAG1 (F: ccttactgttgagactgcaatatcc, R: ctgaagtcccagtatat
acttcacac); RAG2 (F: cccagaagcagtaataatcatcgag, R: atgtgggatgtagtagatc
ttgc); pTa (F: gggtcttacctcagcagttac, R: cctcacacagtgtgacgcag); BCL2 (F:
gactgagtacctgaaccggc, R: gggccaaactgagcagagtc); BAX (F: aagaccagggtg
gttgggac, R: gtaagaaaaatgcccacgtc); and JAK3 (F: agtcagacgtctggagcttc,
R: gtgagcagtgaaggcatgagtc).
Whole-Genome Sequencing and Analysis
DNA from iPSCs was sheared using a Covaris S2 Focused-ultrasonicator:
130-ml samples in microTUBEs were subjected to two 60-s cycles of 10%
duty cycle, intensity of 4, and 200 cycles per burst in frequency sweeping
mode. DNA Chip (DNA 1000 Kit; Agilent Technologies) analysis using an Agi-
lent 2100 Bioanalyzer indicated an average fragment size of 400 bp. Library
preparation was performed using an NEBNext Ultra DNA Library Prep Kit for
Illumina (NEB #E7370), and the final library concentration was determined by
qPCR using a KAPA Illumina Library Quantification Kit (KK4835; KAPA Bio-
systems) and an Applied Biosystems ViiA 7 Real-Time PCR System (Life
Technologies).
Sequencing clusters were produced on the flow cell using an Illumina
TruSeq PE Cluster Kit v.3-cBot-HS (PE-401-3001) and an Illumina cBot.
WGS was performed using an Illumina TruSeq SBS Kit v.3-HS-200 cycles
(FC-401-3001) and an Illumina HiSeq 2500 upgrade to generate 2 3 100
single-index paired-end reads for bioinformatic analysis.ports 12, 1668–1677, September 8, 2015 ª2015 The Authors 1675
Potential off-target sites were identified by aligning the CRISPR/Cas9 guide
sequences to the hg19 reference genome using EMBOSS fuzznuc software
(v.6.6.0.0) (Rice et al., 2000) and allowing for a maximum of three mismatches;
1,193 sites were identified for the first guide sequence (GTGAGATACAGATA
CAGACA) and 257 sites for the second guide sequence (AATGATTTG
CCTGGAATGCC).
All of the reads from the WGS for each sample were mapped to the hg19
reference genome using the BWA (v.0.7.5a) mem algorithm (Li and Durbin,
2010) and duplicate reads were removed using Picard tools (v.1.100) (http://
broadinstitute.github.io/picard/). Local realignment and base quality re-cali-
bration were performed using GATK (v.2.7-2) (McKenna et al., 2010). Both
SNVs and indels were called using GATK HaplotypeCaller. Additionally,
SNVs and indels were separately re-calibrated as described in GATK Best
Practices, and quality filters were applied. Genome STRiP v.2.0 (Handsaker
et al., 2011, 2015) was used to call the large deletions against a background
population of 100 samples from the 1000 Genomes Project. Inversions, dupli-
cations, and translocations were called using Delly v.0.6.3 (Rausch et al.,
2012), and insertions were called using Pindel v.0.2.5a8 (Ye et al., 2009).
Variants from the reference genome that were common to all four iPSC sam-
ples were excluded from CRISPR/Cas9 off-target analysis. The non-excluded
variants were screened using BEDTools (v.2.17.0) (Quinlan and Hall, 2010) to
determine whether they fell within the potential off-target sites ±100 flanking
base pairs. The analysis demonstrated that none of these variants reside
in the off-target sites and suggests that these variants were randomly
accumulated.
All of the functional variants (excluded and non-excluded) with a low allele
frequency (<1% in dbSNP 138, 1000 Genomes, and NHLBI-ESP 6500),
conserved in phastCons 46-way elements (Siepel et al., 2005) and with a
high CADD score (CADDR10) (Kircher et al., 2014) were then annotated using
the ANNOVAR software package (Wang et al., 2010) and screened for known
associations with diseases in ClinVar (v.20140902) (Landrum et al., 2014),
GWAS Catalog (Welter et al., 2014), and COSMIC (v.70) (Forbes et al.,
2008); additionally, we manually screened the variants with a high CADD score
(CADD >20) in HGMD (Stenson et al., 2003). None of these variants, including
the JAK3 C1837T variant, were found to be associated with disease in
the databases queried. Unlike the other variants, however, the JAK3
C1837T (p.R613X) variant (rs149316157) is predicted to be significantly dele-
terious, with a GERP score (Davydov et al., 2010) of 3.85 and a CADD score
of 36; we report here the association of this JAK3 variant with a clinical case
of SCID.ACCESSION NUMBERS
The WGS data can be accessed at the NCBI Sequence Read Archive data-
base with the accession number SRP056149.
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